The Russian vaccine against the coronavirus EpiVacCorona showed 100% efficacy, reported the press service of the national consumer protection office (Rospotrebnadzor).
“The efficiency of the vaccine consists of its immunological and preventive efficacy. According to the results of the first and second phase of clinical trials, the immunological efficacy of the EpiVacCorona vaccine is 100% ", says the statement, according to a Sputnik review.
The EpiVacCorona vaccine is the second developed in the country against the coronavirus. The first, Sputnik V, created by the Nikolái Gamaleya Center for Epidemiology and Microbiology and with funding from the Russian Direct Investment Fund (RDIF) was registered on August 11.
In November, the Russian Health Ministry authorized the Véktor Institute to carry out clinical trials on 3.000 volunteers, including those over 60 years of age. Then, at the beginning of December, Russia sent documents to the World Health Organization (WHO) to examine the possible approval of the biological.
This Monday, the mass vaccination plan for the entire population of this Eurasian nation began in Russia, which exceeds 17 million square kilometers and whose population is located above 140 million inhabitants.